Latest:
Rapid Readouts: Phase 2 JULIET Trial
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kathleen A. Dorritie, MD
Kathleen A. Dorritie, MD, is a hematologist/medical oncologist at the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.
Latest:
Dr Dorritie on the Use of Pirtobrutinib Following Prior BTK Inhibition in CLL
Kathleen A. Dorritie, MD, discusses data that inform the use of pirtobrutinib and liso-cel for the treatment of patients with chronic lymphocytic leukemia.
Daniel H. Ahn, DO, Mayo Clinic
Latest:
ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer
Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.
Melanie A. Sheen, MD
Melanie A. Sheen, MD specializes in hematology and oncology at Ochsner MD Anderson Cancer Center.
Latest:
Dr Sheen on Racial Disparities in Physiology, Genetic Testing in Breast Cancer
Melanie A. Sheen, MD, discusses a study aimed at determining differences in breast composition and assess racial disparities in access to and utilization of genetic counseling.
Ioannis Politikos, MD
Ioannis Politikos, MD, is an assistant attending physician at Memorial Sloan Kettering Cancer Center.
Latest:
Dr Politikos on the Immune Reconstitution Profiles of Orca-T and CD34 Allograft Recipients in Hematologic Malignancies
Ioannis Politikos, MD, discusses data from a study which compared the immune reconstitution profiles of Orca-T with those from CD34 allograft recipients.
Donal McLornan, MBBCh, MRCP, PhD, FRCPath
Donal McLornan, MBBCh, MRCP, PhD, FRCPath, is a consultant, Hematology and Stem Cell Transplantation, University College London Hospitals NHS Foundation Trust.
Latest:
Dr McLornan on the Challenges of Identifying Optimal Timing for Transplantation in Myelofibrosis
Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.
Henry Ford Cancer Institute
Latest:
Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health Disparities
Henry Ford Health + Michigan State University Health Sciences announced its funding of 5 cancer research grants of up to $100,000 each. These 5 grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, is an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center
Latest:
Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.
Ilya Laufer, MD
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades
Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Dr. Judy Garber, Chief of the Division for Cancer Genetics and Prevention at Dana-Farber Cancer
Latest:
Dr. Garber on the Efficacy of Adjuvant Olaparib in High-Risk, HER2-Negative Breast Cancer
Judy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.
Stefano Luminari, MD
Stefano Luminari, MD, is an associate professor of Oncology at the University of Modena and Reggio Emilia in Italy.
Latest:
Dr Luminari on the Safety Profile of Odronextamab in Relapsed/Refractory Follicular Lymphoma
Stefano Luminari, MD, details the safety profile of odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.